We are live on ! Find out more
TXMD icon

TherapeuticsMD

160 hedge funds and large institutions have $237M invested in TherapeuticsMD in 2021 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 62 increasing their positions, 27 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

130% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 27

66% more call options, than puts

Call options by funds: $2.56M | Put options by funds: $1.54M

20% more capital invested

Capital invested by funds: $197M → $237M (+$39.9M)

13% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 24

1% more funds holding

Funds holding: 159160 (+1)

0.17% less ownership

Funds ownership: 1.09%0.91% (-0.17%)

Holders
160
Holders Change
+1
Holders Change %
+0.63%
% of All Funds
2.81%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
27
Increased
62
Reduced
27
Closed
24
Calls
$2.56M
Puts
$1.54M
Net Calls
+$1.01M
Net Calls Change
+$1.11M

TXMD Hedge Fund Activity: Q1 2021 in Review

160 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q1 2021, worth a combined $237M — up 20% from $197M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new TXMD positions and 24 closed out — a net gain of 3 holders — while 62 added to existing stakes and 27 trimmed.

The largest buyer was BlackRock, adding an estimated $9.67M. The largest seller was GMT Capital, exiting entirely with an estimated $7.24M sold.

  • 160 institutional investors held TherapeuticsMD (TXMD) as of Q1 2021, up from 159 in Q4 2020.
  • Funds reported $237M of TherapeuticsMD stock for Q1 2021, up 20% quarter-over-quarter.
  • 27 funds opened new TherapeuticsMD positions in Q1 2021 and 24 closed out, a net change of +3 holders.
  • The largest TherapeuticsMD buyer in Q1 2021 was BlackRock, an estimated $9.67M added.
  • The largest TherapeuticsMD seller in Q1 2021 was GMT Capital, an estimated $7.24M sold.

Based on aggregated 13F filings for Q1 2021.